Evidence map›Paper›PMID 32385092›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2020

3,4-Methylenedioxypyrovalerone: Neuropharmacological Impact of a Designer Stimulant of Abuse on Monoamine Transporters.

Charlotte P Magee, Christopher L German, Yasmeen H Siripathane, Peter S Curtis, David J Anderson, Diana G Wilkins, Glen R Hanson, Annette E Fleckenstein

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Charlotte P MageeSchool of Dentistry (C.P.M., C.L.G., Y.H.S., P.S.C., G.R.H., A.E.F.), Interdepartmental Program in Neuroscience (C.P.M., C.L.G., G.R.H., A.E.F.), Center for Human Toxicology (D.J.A., D.G.W.), and Department of Pathology (D.G.W.), University of Utah, Salt Lake City, Utah.
Christopher L GermanSchool of Dentistry (C.P.M., C.L.G., Y.H.S., P.S.C., G.R.H., A.E.F.), Interdepartmental Program in Neuroscience (C.P.M., C.L.G., G.R.H., A.E.F.), Center for Human Toxicology (D.J.A., D.G.W.), and Department of Pathology (D.G.W.), University of Utah, Salt Lake City, Utah.
Yasmeen H SiripathaneSchool of Dentistry (C.P.M., C.L.G., Y.H.S., P.S.C., G.R.H., A.E.F.), Interdepartmental Program in Neuroscience (C.P.M., C.L.G., G.R.H., A.E.F.), Center for Human Toxicology (D.J.A., D.G.W.), and Department of Pathology (D.G.W.), University of Utah, Salt Lake City, Utah.
Peter S CurtisSchool of Dentistry (C.P.M., C.L.G., Y.H.S., P.S.C., G.R.H., A.E.F.), Interdepartmental Program in Neuroscience (C.P.M., C.L.G., G.R.H., A.E.F.), Center for Human Toxicology (D.J.A., D.G.W.), and Department of Pathology (D.G.W.), University of Utah, Salt Lake City, Utah.
David J AndersonSchool of Dentistry (C.P.M., C.L.G., Y.H.S., P.S.C., G.R.H., A.E.F.), Interdepartmental Program in Neuroscience (C.P.M., C.L.G., G.R.H., A.E.F.), Center for Human Toxicology (D.J.A., D.G.W.), and Department of Pathology (D.G.W.), University of Utah, Salt Lake City, Utah.
Diana G WilkinsSchool of Dentistry (C.P.M., C.L.G., Y.H.S., P.S.C., G.R.H., A.E.F.), Interdepartmental Program in Neuroscience (C.P.M., C.L.G., G.R.H., A.E.F.), Center for Human Toxicology (D.J.A., D.G.W.), and Department of Pathology (D.G.W.), University of Utah, Salt Lake City, Utah.
Glen R HansonSchool of Dentistry (C.P.M., C.L.G., Y.H.S., P.S.C., G.R.H., A.E.F.), Interdepartmental Program in Neuroscience (C.P.M., C.L.G., G.R.H., A.E.F.), Center for Human Toxicology (D.J.A., D.G.W.), and Department of Pathology (D.G.W.), University of Utah, Salt Lake City, Utah.
Annette E FleckensteinSchool of Dentistry (C.P.M., C.L.G., Y.H.S., P.S.C., G.R.H., A.E.F.), Interdepartmental Program in Neuroscience (C.P.M., C.L.G., G.R.H., A.E.F.), Center for Human Toxicology (D.J.A., D.G.W.), and Department of Pathology (D.G.W.), University of Utah, Salt Lake City, Utah fleckenstein@hsc.utah.edu.
University of Utah · US

Funding

Neurochemical and Behavioral Effects of Synthetic CathinonesR01DA039145 · NIDA · UNIVERSITY OF UTAH · PI FLECKENSTEIN, ANNETTE · 2016 to 2020
$1.7M
NIDA NIH HHS R01 DA039145
6 · The paper itself

Abstract

Methylenedioxypyrovalerone (MDPV) is an abused synthetic cathinone, commonly referred to as a "bath salt." Because the dopamine (DA) transporter (DAT) and vesicular monoamine transporter-2 (VMAT-2) are key regulators of both the abuse and neurotoxic potential of structurally and behaviorally related agents, the impact of MDPV on these transporters was investigated. Results revealed that a single in vivo MDPV administration rapidly (within 1 hour) and reversibly increased both rat striatal DAT and VMAT-2 activity, as assessed via [

Indexed as

AnimalsBenzodioxolesBody TemperatureCentral Nervous System StimulantsDesigner DrugsDopamineDopamine Plasma Membrane Transport ProteinsDopaminergic NeuronsFemaleMaleNeostriatumPyrrolidinesRatsRats, Sprague-DawleySubstance-Related DisordersSynthetic CathinoneBenzodioxolesCentral Nervous System StimulantsDesigner DrugsDopamineDopamine Plasma Membrane Transport ProteinsPyrrolidinesSlc18a2 protein, ratSynthetic CathinoneVesicular Monoamine Transport Proteins

Identifiers

PMID32385092
PMCPMC7366288
OpenAlexW3022613486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.